Johnson & Johnson (NYSE:JNJ) Stock Holdings Lessened by J. L. Bainbridge & Co. Inc.

J. L. Bainbridge & Co. Inc. lowered its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 2.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 168,219 shares of the company’s stock after selling 3,663 shares during the period. Johnson & Johnson accounts for about 4.2% of J. L. Bainbridge & Co. Inc.’s holdings, making the stock its 8th biggest position. J. L. Bainbridge & Co. Inc.’s holdings in Johnson & Johnson were worth $27,480,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Morton Brown Family Wealth LLC grew its holdings in shares of Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after purchasing an additional 78 shares in the last quarter. Goodman Advisory Group LLC bought a new stake in Johnson & Johnson during the second quarter valued at approximately $39,000. First Bank & Trust increased its holdings in shares of Johnson & Johnson by 69.6% in the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock worth $67,000 after buying an additional 156 shares during the last quarter. Heritage Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $84,000. Finally, Timber Creek Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 225.0% during the 3rd quarter. Timber Creek Capital Management LLC now owns 650 shares of the company’s stock worth $106,000 after acquiring an additional 450 shares during the last quarter. Institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $168.31 on Wednesday. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The stock’s 50-day moving average is $175.98 and its 200 day moving average is $171.06. The company has a market cap of $440.04 billion, a PE ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating analysts’ consensus estimates of $2.23 by $0.12. The company had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.13 earnings per share. Sell-side analysts anticipate that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s payout ratio is currently 62.95%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 76,923 shares of the stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the transaction, the executive vice president now owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CAO Robert J. Decker sold 16,928 shares of the stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $175.00, for a total value of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,707,775. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer L. Taubert sold 76,923 shares of the business’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the sale, the executive vice president now directly owns 126,456 shares in the company, valued at approximately $22,354,891.68. The disclosure for this sale can be found here. In the last three months, insiders have sold 233,611 shares of company stock valued at $40,960,735. 0.35% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Citigroup raised their price target on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. StockNews.com began coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. SVB Leerink reduced their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Sanford C. Bernstein lowered their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Finally, Credit Suisse Group initiated coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 target price on the stock. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $181.75.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.